Cancer stem cells and differentiation therapy
Cancer stem cells can generate tumors from only a small number of cells, whereas differentiated cancer cells cannot. The prominent feature of cancer stem cells is its ability to self-renew and differentiate into multiple types of cancer cells. Cancer stem cells have several distinct tumorigenic abil...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IOS Press
2017-10-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317729933 |
id |
doaj-9e18595eb971406d9c5549087d88168a |
---|---|
record_format |
Article |
spelling |
doaj-9e18595eb971406d9c5549087d88168a2021-05-02T22:32:26ZengIOS PressTumor Biology1423-03802017-10-013910.1177/1010428317729933Cancer stem cells and differentiation therapyXiong Jin0Xun Jin1Hyunggee Kim2Institute of Animal Molecular Biotechnology, Korea University, Seoul, Republic of KoreaInstitute of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaInstitute of Animal Molecular Biotechnology, Korea University, Seoul, Republic of KoreaCancer stem cells can generate tumors from only a small number of cells, whereas differentiated cancer cells cannot. The prominent feature of cancer stem cells is its ability to self-renew and differentiate into multiple types of cancer cells. Cancer stem cells have several distinct tumorigenic abilities, including stem cell signal transduction, tumorigenicity, metastasis, and resistance to anticancer drugs, which are regulated by genetic or epigenetic changes. Like normal adult stem cells involved in various developmental processes and tissue homeostasis, cancer stem cells maintain their self-renewal capacity by activating multiple stem cell signaling pathways and inhibiting differentiation signaling pathways during cancer initiation and progression. Recently, many studies have focused on targeting cancer stem cells to eradicate malignancies by regulating stem cell signaling pathways, and products of some of these strategies are in preclinical and clinical trials. In this review, we describe the crucial features of cancer stem cells related to tumor relapse and drug resistance, as well as the new therapeutic strategy to target cancer stem cells named “differentiation therapy.”https://doi.org/10.1177/1010428317729933 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiong Jin Xun Jin Hyunggee Kim |
spellingShingle |
Xiong Jin Xun Jin Hyunggee Kim Cancer stem cells and differentiation therapy Tumor Biology |
author_facet |
Xiong Jin Xun Jin Hyunggee Kim |
author_sort |
Xiong Jin |
title |
Cancer stem cells and differentiation therapy |
title_short |
Cancer stem cells and differentiation therapy |
title_full |
Cancer stem cells and differentiation therapy |
title_fullStr |
Cancer stem cells and differentiation therapy |
title_full_unstemmed |
Cancer stem cells and differentiation therapy |
title_sort |
cancer stem cells and differentiation therapy |
publisher |
IOS Press |
series |
Tumor Biology |
issn |
1423-0380 |
publishDate |
2017-10-01 |
description |
Cancer stem cells can generate tumors from only a small number of cells, whereas differentiated cancer cells cannot. The prominent feature of cancer stem cells is its ability to self-renew and differentiate into multiple types of cancer cells. Cancer stem cells have several distinct tumorigenic abilities, including stem cell signal transduction, tumorigenicity, metastasis, and resistance to anticancer drugs, which are regulated by genetic or epigenetic changes. Like normal adult stem cells involved in various developmental processes and tissue homeostasis, cancer stem cells maintain their self-renewal capacity by activating multiple stem cell signaling pathways and inhibiting differentiation signaling pathways during cancer initiation and progression. Recently, many studies have focused on targeting cancer stem cells to eradicate malignancies by regulating stem cell signaling pathways, and products of some of these strategies are in preclinical and clinical trials. In this review, we describe the crucial features of cancer stem cells related to tumor relapse and drug resistance, as well as the new therapeutic strategy to target cancer stem cells named “differentiation therapy.” |
url |
https://doi.org/10.1177/1010428317729933 |
work_keys_str_mv |
AT xiongjin cancerstemcellsanddifferentiationtherapy AT xunjin cancerstemcellsanddifferentiationtherapy AT hyunggeekim cancerstemcellsanddifferentiationtherapy |
_version_ |
1721486846653890560 |